Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 14/20 | 1.00 |
| ▸ | AGXT | P21549 | 12/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL662679 | 0.98 | IDO1 (1.00) | IDO1AGXTCYP3A4TAAR1 | |
| SCHEMBL14218208 | 0.92 | IDO1 (0.85) | IDO1AGXTCYP3A4TAAR1MAOB | |
| SCHEMBL437710 | 0.84 | IDO1 (0.71) | IDO1AGXTCYP3A4 | |
| SCHEMBL6667381 | 0.82 | IDO1 (0.69) | IDO1TAAR1MAOB | |
| SCHEMBL30253988 | 0.80 | IDO1 (0.67) | IDO1TAAR1MAOB | |
| SCHEMBL12379 | 0.80 | IDO1 (0.67) | IDO1TAAR1MAOB | |
| SCHEMBL31712164 | 0.79 | IDO1 (0.66) | IDO1TAAR1MAOB | |
| SCHEMBL1521252 | 0.79 | AGXT (0.73) | IDO1AGXTCYP3A4 | |
| SCHEMBL1145657 | 0.78 | IDO1 (0.64) | IDO1TAAR1MAOB | |
| SCHEMBL11302792 | 0.78 | IDO1 (0.64) | IDO1TAAR1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | claimed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | claimed |
| EP-2227233-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | claimed |
| EP-4640688-A1 | AVERMECTIN DERIVATIVE | Meiji Seika Pharma Co., Ltd. (JP) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024135828-A1 | AVERMECTIN DERIVATIVE | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 2024-06-27 | — | — | WO | disclosed |
| US-8716346-B2 | Alkylating agent combinations in the treatment of cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| US-8536157-B2 | Non-steroidal compounds | THE UNIVERSITY OF MELBOURNE (AU) | 2013-09-17 | — | — | US | disclosed |
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | disclosed |
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | GERSON STANTON L (US) | 2012-03-15 | — | — | US | disclosed |
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) | 2012-02-23 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2007059116-A2 | GELDANAMYCIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ABRAXIS BIOSCIENCE, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| CN-1218943-C | 4-pyrimidinyl-N-acyl-L-phenylalanine compounds | HOFFMANN LA ROCHE (CH) | 2005-09-14 | — | — | CN | disclosed |
| WO-2005021606-A1 | METHODS OF PRODUCING NUCLEOPHILIC POLYOLEFINS AND USES THEREOF | HONEYWELL INTERNATIONAL INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| CN-1407972-A | 4-pyrimidinyl-N-acyl-L-phenylalanine compounds | HOFFMANN LA ROCHE (CH) | 2003-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885AGXT 365/4885CYP3A4 413/4885 |
| US-20120065145-A1 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER | UNG, TOP2A, OGG1 | IDO1 4025/4885AGXT 2638/4885CYP3A4 4711/4885 |
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | PTGES2, PTGES, PTGES3 | IDO1 2049/4885AGXT 2786/4885CYP3A4 500/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885AGXT 285/4885CYP3A4 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.